Experimental combo shows early promise for tough liver cancer
NCT ID NCT06354387
First seen Mar 30, 2026 · Last updated May 07, 2026 · Updated 4 times
Summary
This early-phase study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. The study is now complete, but results are not yet widely reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMUH
Taichung, Taiwan
Conditions
Explore the condition pages connected to this study.